Literature DB >> 16401475

Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension.

Steeve Provencher1, Philippe Herve, Xavier Jais, Didier Lebrec, Marc Humbert, Gerald Simonneau, Olivier Sitbon.   

Abstract

BACKGROUND & AIMS: It has been suggested that beta-blockers might be harmful in pulmonary arterial hypertension. However, no study has evaluated the effect of beta-blockers in these patients. The aim of this study was to investigate the effect of beta-blockers on exercise capacity and pulmonary hemodynamics in patients with portopulmonary hypertension receiving beta-blockers for the prophylaxis of variceal bleeding.
METHODS: Ten consecutive patients with moderate to severe portopulmonary hypertension (mean pulmonary artery pressure of 52 [10] mm Hg) underwent a 6-minute walk test and a right heart catheterization at baseline and 2 (1) months after beta-blocker withdrawal.
RESULTS: Following beta-blocker withdrawal, 9 of 10 patients increased their 6-minute walked distance with a mean increase in the whole group of 79 (78) meters (P = .01). Cardiac output increased by 28% (P < .01) with no change in mean pulmonary artery pressure, resulting in a 19% decrease in pulmonary vascular resistance (P < .01). Increases in cardiac output were related to a 25% increase in heart rate (P < .01), whereas stroke volume was unchanged (P = .65). The improvements in exercise tolerance were associated with increases in chronotropic response (maximal heart rate minus resting heart rate) from 18 (9) to 34 (12) beats/min (P < .01) during the 6-minute walk test.
CONCLUSIONS: In patients with moderate to severe portopulmonary hypertension, beta-blockers are associated with significant worsening in exercise capacity and pulmonary hemodynamics. These deleterious effects support the contraindication of beta-blockers in patients with portopulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16401475     DOI: 10.1053/j.gastro.2005.10.013

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  49 in total

Review 1.  The adrenergic system in pulmonary arterial hypertension: bench to bedside (2013 Grover Conference series).

Authors:  Michael R Bristow; Robert A Quaife
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

Review 2.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Portopulmonary hypertension.

Authors:  Ravi P Nayak; Dechun Li; George M Matuschak
Journal:  Curr Gastroenterol Rep       Date:  2009-02

Review 4.  Neurohormonal modulation as therapeutic avenue for right ventricular dysfunction in pulmonary artery hypertension: till the dawn, waiting.

Authors:  Roy Emanuel; Astha Chichra; Nirav Patel; Thierry H Le Jemtel; Abhishek Jaiswal
Journal:  Ann Transl Med       Date:  2018-08

Review 5.  Hepato-cardiac disorders.

Authors:  Yasser Mahrous Fouad; Reem Yehia
Journal:  World J Hepatol       Date:  2014-01-27

Review 6.  Do we have two hearts? New insights in right ventricular function supported by myocardial imaging echocardiography.

Authors:  Antonio Vitarelli; Claudio Terzano
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

7.  [Medical therapy of heart and lung diseases. Effects on the respective other organ].

Authors:  S Möhlenkamp; G Weinreich; T Neumann; T Voshaar; H Teschler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

8.  Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series).

Authors:  Wei Tan; Krishna Madhavan; Kendall S Hunter; Daewon Park; Kurt R Stenmark
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

Review 9.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

Review 10.  Novel therapeutic approaches to preserve the right ventricle.

Authors:  Samar Farha; Erika L Lundgrin; Serpil C Erzurum
Journal:  Curr Heart Fail Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.